BridgeBio Pharma (BBIO) Expected to Release Quarterly Earnings on Wednesday

Key Points

• BridgeBio Pharma is expected to report Q3 2026 earnings on October 28 after the market closes, with analysts forecasting a loss of $0.5437 per share and revenue of $288.74 million.
• In the previous quarter, the company posted a larger-than-expected loss of $0.78 per share but exceeded revenue estimates with $243.68 million, up 120.4% year over year.
• BBIO shares opened at $67.55, below their 50-day and 200-day moving averages, while analysts maintain a “Moderate Buy” consensus and an average price target of $104.90.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) is expected to be releasing its Q3 2026 results after the market closes on Wednesday, October 28th. Analysts expect the company to post earnings of ($0.5437) per share and revenue of $288.74 million for the quarter. Individuals are encouraged to explore the company's upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, October 28, 2026 at 4:30 PM ET.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.78) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.20). The company had revenue of $243.68 million for the quarter, compared to analyst estimates of $220.91 million. The firm's revenue for the quarter was up 120.4% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.95) earnings per share. On average, analysts expect BridgeBio Pharma to post ($2.63) EPS for the current fiscal year and ($0.57) EPS for the next fiscal year.

BridgeBio Pharma Stock Down 0.6%

Shares of NASDAQ:BBIO opened at $67.55 on Wednesday. The stock's 50-day moving average is $72.09 and its 200-day moving average is $73.25. BridgeBio Pharma has a 52-week low of $52.75 and a 52-week high of $93.42.

Insider Buying and Selling

In related news, CAO Maricel Apuli sold 2,000 shares of the stock in a transaction on Thursday, July 30th. The shares were sold at an average price of $80.06, for a total transaction of $160,120.00. Following the transaction, the chief accounting officer owned 127,401 shares of the company's stock, valued at approximately $10,199,724.06. This trade represents a 1.55% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Neil Kumar sold 10,000 shares of the stock in a transaction dated Thursday, September 17th. The shares were sold at an average price of $69.08, for a total value of $690,800.00. Following the sale, the chief executive officer owned 495,686 shares of the company's stock, valued at $34,241,988.88. This represents a 1.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 56,980 shares of company stock valued at $4,578,119. Company insiders own 14.23% of the company's stock.

Analyst Ratings Changes

A number of analysts have weighed in on the company. Bank of America upped their price target on BridgeBio Pharma from $101.00 to $104.00 and gave the company a "buy" rating in a research report on Tuesday, August 11th. HC Wainwright reaffirmed a "buy" rating on shares of BridgeBio Pharma in a report on Tuesday, October 6th. JPMorgan Chase & Co. raised their target price on shares of BridgeBio Pharma from $100.00 to $111.00 and gave the company an "overweight" rating in a research note on Wednesday, August 12th. Morgan Stanley decreased their target price on BridgeBio Pharma from $98.00 to $97.00 and set an "overweight" rating for the company in a research report on Tuesday, August 11th. Finally, Canaccord Genuity Group increased their price target on BridgeBio Pharma from $104.00 to $106.00 and gave the stock a "buy" rating in a report on Wednesday, August 12th. One research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $104.90.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for genetically driven diseases. The company operates through a portfolio of subsidiary and affiliated biotechnology businesses, with research programs spanning rare diseases, oncology, cardiology and other conditions linked to underlying genetic or molecular causes.

BridgeBio's portfolio includes therapies designed to address the root mechanisms of disease rather than primarily treating symptoms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.